Drug Patent Watch
FEBRUARY 18, 2022
This chart shows the pharmaceutical companies with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
FEBRUARY 18, 2022
Today’s guest post comes from Garry Marshall, Senior Director of Business Strategy at Wolters Kluwer, Health. Garry discusses healthcare business vertical integration and its effect on care quality for patients and on providers' work experiences. To learn more, download the Wolters Kluwer Expert Insight article Vertical Integration Strategies: Using Data to Align Partners and Reduce Variation in Care.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Broad Institute
FEBRUARY 18, 2022
Explainers By admin February 18, 2022 Breadcrumb Home Explainers
The Pharma Data
FEBRUARY 18, 2022
Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia to establish mRNA vaccine production. At the European Union – African Union summit in Brussels today WHO Director-General, Dr Tedros Adhanom Ghebreyesus, announced the first six countries that will receive the technology needed to produce mRNA vaccines on the African continent. Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia all applied and have been selected as recipients.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drug Patent Watch
FEBRUARY 17, 2022
This chart shows the drugs with the most patents in Germany. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Germany? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Olympian Clinical Research
FEBRUARY 17, 2022
Prurigo nodularis (PN) is a rare skin disorder that causes hard, itchy, or painful bumps to appear on the skin. Symptoms of PN usually begin to appear in middle-aged adults, but it can affect people of all ages. What Does Prurigo Nodularis Look Like? The primary symptom of prurigo nodularis is the appearance of firm, itchy or painful lumps called nodules on the skin.
The Strateos Blog: Drug Discovery
FEBRUARY 16, 2022
Strateos is pleased to be taking part alongside other thought leaders in the field of lab automation at PharmaIQ Live: SmartLab Digital 2022 on March 8-9, 2022. John Harman, Strateos’ Senior Director of Product Management will be presenting a talk focused on accelerating drug discovery workflows through automation, robotics, and lab digitalization.
Drug Patent Watch
FEBRUARY 12, 2022
This chart shows the drugs with the most patents in Finland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
FEBRUARY 15, 2022
– La te-breaking data from Cohort H of EV-103 trial to be presented at the 2022 ASCO Genitourinary Cancers Symposium –. – Activity, tolerability of enfortumab vedotin support ongoing investigation in Phase 3 trials–. Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced the initial results from Cohort H of the EV-103 trial investigating PADCEV ® (enfortumab vedotin-ejfv) as a monotherapy in patients with muscle-invasiv
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Crown Bioscience
FEBRUARY 14, 2022
Discover how high-content screening (HCS) can be used with 3D in vitro models to drive the discovery and development of novel oncology and immuno-oncology therapeutics.
National Drug & Alcohol Research Centre Blog
FEBRUARY 13, 2022
Tom Santo Jr. To reduce the likelihood of opioid use disorder (OUD) among people prescribed opioids for chronic non-cancer pain (CNCP), it is important to identify individual risk factors for OUD among this population. However, until now, little has been known about the relationship between a childhood trauma and OUD risk among people prescribed opioids for CNCP.
Drug Patent Watch
FEBRUARY 15, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Switzerland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Switzerland? appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
FEBRUARY 14, 2022
Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), Buti Manamela, Deputy Minister of Higher Education and Training of the Republic of South Africa, Dr Blade Nzimande, Minister of Higher Education, Science and Technology of South Africa, Dr Joe Phaahla, Minister of Health of South Africa and Meryame Kitir, Minister of Development Cooperation and Urban Policy of Belgium today visit a number of public and private sector partners that are collaborating to develop
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The Anticancer Fund
FEBRUARY 17, 2022
17 February 2022 Language EN Drug repurposing is a strategy for identifying new uses for approved drugs, outside the scope of the original indication. It is one of the focus areas of the Anticancer Fund. Below, we have listed recent findings about the repurposing of generic drugs in oncology. Our intention is to help bring these findings to the attention of the broader cancer research community.
Drug & Device Law
FEBRUARY 18, 2022
As we write this, our firm’s “return to office” date is less than two weeks away. We will be delighted to see, hug, and collaborate in person with colleagues we’ve missed for two long years (computer visages notwithstanding), though we confess to panic at the prospect of “real clothes.” And shoes. It’s all a bit of a mixed bag, as is today’s case.
Drug Patent Watch
FEBRUARY 18, 2022
Annual Drug Patent Expirations for IMVEXXY Imvexxy is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are fourteen patents…. The post New patent for Therapeuticsmd Inc drug IMVEXXY appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
FEBRUARY 13, 2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to extend their rolling submission to the U.S. Food and Drug Administration (FDA) seeking to amend the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine to include children 6 months through 4 years of age, which had been requested by FDA. The trial in children 6 months through 4 years of age is ongoing and data on the first two 3 µg doses in this age group are being shared with the FDA on an ongoing ba
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
FEBRUARY 18, 2022
Annual Drug Patent Expirations for DEFITELIO Defitelio is a drug marketed by Jazz Pharms Inc and is included in one NDA. It is available from one supplier. There is one…. The post New patent for Jazz Pharms drug DEFITELIO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 18, 2022
Annual Drug Patent Expirations for VELPHORO Velphoro is a drug marketed by Vifor Fresenius and is included in one NDA. It is available from one supplier. There are nine patents…. The post New patent for Vifor Fresenius drug VELPHORO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 18, 2022
Annual Drug Patent Expirations for ORLADEYO Orladeyo is a drug marketed by Biocryst and is included in one NDA. There are five patents protecting this drug. This drug has forty-eight…. The post New patent for Biocryst drug ORLADEYO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 18, 2022
Annual Drug Patent Expirations for LUMAKRAS Lumakras is a drug marketed by Amgen Inc and is included in one NDA. It is available from one supplier. The generic ingredient in…. The post New patent for Amgen Inc drug LUMAKRAS appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
FEBRUARY 17, 2022
Annual Drug Patent Expirations for FOTIVDA Fotivda is a drug marketed by Aveo Pharms and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Aveo Pharms drug FOTIVDA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 16, 2022
This chart shows the pharmaceutical companies with the most patents in Malaysia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Malaysia? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 16, 2022
Annual Drug Patent Expirations for PREVACID+IV Prevacid Iv is a drug marketed by Takeda Pharms Na and is included in one NDA. There is one patent protecting this drug. The…. The post New patent expiration for Takeda Pharms drug PREVACID IV appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 16, 2022
Annual Drug Patent Expirations for CYSVIEW+KIT Cysview Kit is a drug marketed by Photocure Asa and is included in one NDA. It is available from one supplier. There is one…. The post New patent for Photocure Asa drug CYSVIEW KIT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 16, 2022
Annual Drug Patent Expirations for GIVLAARI Givlaari is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are twelve patents protecting this drug. This drug…. The post New patent for Alnylam Pharms drug GIVLAARI appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
98 
Let's personalize your content